What the product information says
We searched the US labels for Wegovy®, Zepbound® and the other GLP-1 medicines on this site, the EU product information and the Canadian monographs for thrombosis, embolism and related terms. None lists them as a reaction from trials or from reports after approval [1][2][3][4]. The only mention we found was a cardiovascular trial describing how many participants already took antithrombotic medicines, which is background information, not a side effect.
Absence from a label means clots were not reported often enough, or differently enough from placebo, to be listed. It does not settle the question, which is why the studies below matter.
| Study type and size | Comparison | Finding | Main limit |
|---|---|---|---|
| Meta-analysis, 27 randomised trials, 84,003 patients [5] | GLP-1 vs placebo | Overall clots: no significant difference. Lung clots: fewer (risk ratio 0.60). Leg clots: no significant difference. | Clots were rare and not the trials’ main outcome |
| Meta-analysis, 39 randomised trials, 70,499 participants [6] | GLP-1 vs placebo or other diabetes drugs | Overall clots: non-significant rise. Leg clots: more (odds ratio 1.64), especially in trials longer than 1.5 years | Same limit; different trial selection and methods |
| Cohort emulating a trial, 540,258 people with type 2 diabetes [7] | GLP-1 vs DPP-4 inhibitor | Fewer clots at one year: 6.1 vs 7.6 per 1,000 person-years | Observational; one year only |
| US Veterans Affairs cohort [8] | GLP-1 vs usual care | Lower risk of coagulation disorders among 175 outcomes | Observational; broad outcome group |
| Case report, one woman on tirzepatide [9] | — | Unprovoked leg clot within months of starting; tests for clotting disorders negative | A single case cannot show cause or frequency |
Why the studies disagree
Both meta-analyses pooled randomised trials, but they chose different trials, used different statistical methods and compared GLP-1 medicines with different groups. The first included only placebo-controlled trials and found the overall effect leaning towards fewer clots, with a clear reduction in pulmonary embolism [5]. The second also included trials against other diabetes medicines and found more deep vein thrombosis, mostly in long cardiovascular outcome trials [6].
In none of these trials were clots the main thing being measured, so events were recorded as side effects rather than confirmed by a standard process. When an outcome is this rare, a handful of events can move the result. The honest summary is that a small increase in leg clots cannot be ruled out and a reduction in lung clots is also possible; neither has been proven.
How a GLP-1 medicine could affect clot risk
- Proposed to lower risk: obesity is a recognised risk factor for clots [11], so weight loss could in principle reduce risk. Laboratory work cited by one research group suggests GLP-1 medicines may dampen platelet activation [7]. Neither has been confirmed as a clinical effect.
- Proposed to raise risk: the second meta-analysis did not identify a mechanism for the extra leg clots it found [6].
- General: surgery, injury, long periods of sitting, estrogen-containing contraceptives or hormone therapy, pregnancy, cancer, older age and earlier clots all raise risk, and the more factors combine, the higher it climbs [11].
Where GLP-1 treatment meets known risk factors
Some situations deserve thought because they combine with a GLP-1 medicine, not because the medicine is proven to cause clots.
- Contraception. The tirzepatide label advises a non-oral or added barrier method for a period after starting and after each dose increase [2]. Some non-oral methods, such as patches and rings, contain estrogen, which CDC lists as a clot risk factor [12]. Choosing a method is a conversation for your prescriber.
- Surgery. Major surgery, particularly of the abdomen, pelvis, hips or legs, raises clot risk [11]. GLP-1 labels separately ask patients to tell their care team about the medicine before procedures under anaesthesia [2].
- Travel. Journeys of more than four hours by air, car, bus or train raise risk, mostly in people who already have other risk factors, including obesity [12].
What may help
CDC advises moving around as soon as possible after being confined to bed, and talking to a doctor about compression stockings or preventive medicine if you are at risk [10]. On trips longer than four hours, it suggests walking about every one to two hours, wearing loose clothes and exercising the legs while seated by raising and lowering the heels and toes and tightening the calf muscles [10][12].
If you have had a clot before, have a family history or take estrogen, tell your prescriber before starting a GLP-1 medicine and before planned surgery or long travel. Do not stop a GLP-1 medicine or start any blood thinner on your own.
Wegovy® is a registered trademark of Novo Nordisk A/S. Zepbound® is a registered trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly and Company.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Sudden difficulty breathing, chest pain that worsens with a deep breath or cough, or coughing up blood | Emergency services (112/911) | Emergency | CDC [10] |
| Fast or irregular heartbeat, lightheadedness or fainting | Emergency services (112/911) | Emergency | CDC [10][12] |
| Swelling, pain or tenderness, warmth or redness in one leg or arm | A doctor as soon as possible | Today | CDC [10] |
| A past clot or a family history, with surgery or long travel coming up | Your prescriber, beforehand | At your next appointment | CDC [11][12] |
| Questions about contraception and clot risk while on a GLP-1 | Your prescriber | At your next appointment | Zepbound® label [2]; CDC [12] |
